ClinicalTrials.gg
CompletedNCT01888497Updated Feb 21, 2021Results posted

Next-Day Residual Effects of Gabapentin, Diphenhydramine and Triazolam on Simulated Driving Performance in Normal Volunteers

A Phase 3 interventional study of Gabapentin and Diphenhydramine citrate in Healthy, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 4 sites in United States. Open to participants aged 25 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-02-21.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
59
Allocation
Randomized
Ages
25 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing gabapentin in Sleep Initiation and Maintenance Disorders — none open to participants now, none under way, none of them phase 3. Gabapentin · Sleep Initiation and Maintenance Disorders.

Enrollment
9th of 14
59 · median 283
Started
2013
the only one that year
Phase 3
9 of 14
none open now
Registered
13th of 14
by date
Lead sponsor
9 of 14
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Among the 14 studies testing gabapentin in Sleep Initiation and Maintenance Disorders, this one is the 9th largest by enrollment, is the only one that started in 2013, is one of 9 in phase 3, and was the 13th registered.

Sleep Initiation and Maintenance Disorders

2,729 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 731 are open to participants now.

Browse Sleep Initiation and Maintenance Disorders studies →

Open to participants now

None of the 14 studies testing gabapentin in Sleep Initiation and Maintenance Disorders is open now. The open studies under Sleep Initiation and Maintenance Disorders, anywhere →

Where they have run

About gabapentin

Gabapentin: first FDA approval 1993 (NEURONTIN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 390 Sleep Initiation and Maintenance Disorders studies recruiting now, 153 (39%) set no upper age limit and 207 (53%) stop at 75 or younger; 59 take children under 18; 109 take healthy volunteers.

This study: 25 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 14 studies testing gabapentin in Sleep Initiation and Maintenance Disorders as a file.
02

Study summary

This study will examine the next-day residual effects of a nighttime dose of gabapentin 250 mg, diphenhydramine citrate 76 mg and triazolam 0.5 mg compared to placebo and each other on simulated driving performance in normal volunteer subjects. It will also examine other measures of next-day performance and next-day sleepiness.

03

Conditions studied

  • Healthy

Keywords

  • Sleeplessness
04

Who can participate

Ages eligible
25 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy males and females of non-, 25-55 years of age
  • Valid driver's license

Exclusion criteria

Exclusion Criteria:

  • Psychiatric disorder
  • Recent history of neurological disorder, such as seizures, stroke, multiple sclerosis, or head trauma
  • Recent histroy or current treatment for sleep disorder
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
59 participants (actual)

Study arms

  • Experimental
    Arm A

    Drug: Gabapentin

  • Experimental
    Arm B

    Drug: Diphenhydramine citrate

  • Active comparator
    Arm C

    Drug: Triazolam

  • Placebo comparator
    Arm D

    Drug: Placebo

Interventions

  • 250 mg, oral, prior to bedtime on the night before performance testing

  • 76 mg, oral, prior to bedtime on the night before performance testing

  • 0.5 mg, oral, prior to bedtime on the night before performance testing

  • DrugPlacebo

    Oral, prior to bedtime on the night before performance testing

06

What researchers measure

Primary outcomes

  1. Standard Deviation of Lateral Position (SDLP)

    Driving performance assessment for the participants were measured by simulated driving test using Cognitive Research Corporation Driving Simulator (CRCDS-MiniSim). The assessment was performed after 45 minutes of awakening from approximately 6.5 hours of sleep on testing day (after 7.25 hours of study drug administration). SDLP was used to assess driver's ability to track their lane and was the standard deviation of lane positions through the entire drive.

    Time frame: 7.25 hours post-dose

Secondary outcomes

  1. Speed Deviation

    Driving performance assessment for the participants were measured by simulated driving test using Cognitive Research Corporation Driving Simulator (CRCDS-MiniSim). The assessment was performed after 45 minutes of awakening from approximately 6.5 hours of sleep on testing day (after 7.25 hours of study drug administration). Standard deviation of speed was reported in the outcome measure.

    Time frame: 7.25 hours post dose

  2. Lane Exceedance

    Driving performance assessment for the participants were measured by simulated driving test using Cognitive Research Corporation Driving Simulator (CRCDS-MiniSim). The assessment was performed after 45 minutes of awakening from approximately 6.5 hours of sleep on testing day (after 7.25 hours of study drug administration). Mean lanes excursed/exceeded was reported in the outcome measure.

    Time frame: 7.25 hours post-dose

07

Results

Posted Feb 5, 2021

Participant flow

First Intervention Period
Participant flow — First Intervention Period
MilestoneDiphenhydramine Citrate, Gabapentin, Placebo, TriazolamGabapentin, Triazolam, Diphenhydramine Citrate, PlaceboTriazolam, Placebo, Gabapentin, Diphenhydramine CitratePlacebo, Diphenhydramine Citrate, Triazolam, Gabapentin
Started13141517
Completed13141517
Not completed0000
Washout Period 1
Participant flow — Washout Period 1
MilestoneDiphenhydramine Citrate, Gabapentin, Placebo, TriazolamGabapentin, Triazolam, Diphenhydramine Citrate, PlaceboTriazolam, Placebo, Gabapentin, Diphenhydramine CitratePlacebo, Diphenhydramine Citrate, Triazolam, Gabapentin
Started13141517
Completed13141416
Not completed0011
Withdrew: Withdrawal by subject0011
Second Intervention Period
Participant flow — Second Intervention Period
MilestoneDiphenhydramine Citrate, Gabapentin, Placebo, TriazolamGabapentin, Triazolam, Diphenhydramine Citrate, PlaceboTriazolam, Placebo, Gabapentin, Diphenhydramine CitratePlacebo, Diphenhydramine Citrate, Triazolam, Gabapentin
Started13141416
Completed13141416
Not completed0000
Washout Period 2
Participant flow — Washout Period 2
MilestoneDiphenhydramine Citrate, Gabapentin, Placebo, TriazolamGabapentin, Triazolam, Diphenhydramine Citrate, PlaceboTriazolam, Placebo, Gabapentin, Diphenhydramine CitratePlacebo, Diphenhydramine Citrate, Triazolam, Gabapentin
Started13141416
Completed13141414
Not completed0002
Withdrew: Adverse event0001
Withdrew: Withdrawal by subject0001
Third Intervention Period
Participant flow — Third Intervention Period
MilestoneDiphenhydramine Citrate, Gabapentin, Placebo, TriazolamGabapentin, Triazolam, Diphenhydramine Citrate, PlaceboTriazolam, Placebo, Gabapentin, Diphenhydramine CitratePlacebo, Diphenhydramine Citrate, Triazolam, Gabapentin
Started13141414
Completed13141414
Not completed0000
Washout Period 3
Participant flow — Washout Period 3
MilestoneDiphenhydramine Citrate, Gabapentin, Placebo, TriazolamGabapentin, Triazolam, Diphenhydramine Citrate, PlaceboTriazolam, Placebo, Gabapentin, Diphenhydramine CitratePlacebo, Diphenhydramine Citrate, Triazolam, Gabapentin
Started13141414
Completed13141414
Not completed0000
Fourth Intervention Period
Participant flow — Fourth Intervention Period
MilestoneDiphenhydramine Citrate, Gabapentin, Placebo, TriazolamGabapentin, Triazolam, Diphenhydramine Citrate, PlaceboTriazolam, Placebo, Gabapentin, Diphenhydramine CitratePlacebo, Diphenhydramine Citrate, Triazolam, Gabapentin
Started13141414
Completed13141414
Not completed0000

Outcome measures

PrimaryStandard Deviation of Lateral Position (SDLP)

Driving performance assessment for the participants were measured by simulated driving test using Cognitive Research Corporation Driving Simulator (CRCDS-MiniSim). The assessment was performed after 45 minutes of awakening from approximately 6.5 hours of sleep on testing day (after 7.25 hours of study drug administration). SDLP was used to assess driver's ability to track their lane and was the standard deviation of lane positions through the entire drive.

Time frame:
7.25 hours post-dose
Reported as:
Mean · centimeter (cm)
Standard Deviation of Lateral Position (SDLP)
centimeter (cm)PlaceboGabapentinDiphenhydramine CitrateTriazolam
Standard Deviation of Lateral Position (SDLP)33.2 ± 8.034.2 ± 10.035.4 ± 8.947.4 ± 12.0
Statistical analysis
  • Placebo vs Triazolam · Wilcoxon Rank Sum test · p = <0.001 (Statistical comparison was performed at a two-sided significance level of 0.05.) · Hodges-lehman estimate: 13.82 · 95% CI 10.85 to 17.40Hodges-Lehman estimate of treatment difference was reported.
  • Placebo vs Gabapentin · Hodges-lehman estimate: 0.55 · 95% CI -0.66 to 2.33Hodges-Lehman estimate of treatment difference was reported.
  • Gabapentin vs Diphenhydramine Citrate · Wilcoxon Rank Sum test · p = 0.134 (Statistical comparison was performed at a two-sided significance level of 0.05.) · Hodges-lehman estimate: 1.02 · 95% CI -0.39 to 2.51Hodges-Lehman estimate of treatment difference was reported.
  • Placebo vs Diphenhydramine Citrate · Wilcoxon Rank Sum test · p = <0.001 (Statistical comparison was performed at a two-sided significance level of 0.05.) · Hodges-lehman estimate: 2.37 · 95% CI 1.01 to 3.98Hodges-Lehman estimate of treatment difference was reported.
SecondarySpeed Deviation

Driving performance assessment for the participants were measured by simulated driving test using Cognitive Research Corporation Driving Simulator (CRCDS-MiniSim). The assessment was performed after 45 minutes of awakening from approximately 6.5 hours of sleep on testing day (after 7.25 hours of study drug administration). Standard deviation of speed was reported in the outcome measure.

Time frame:
7.25 hours post dose
Reported as:
Mean · meters per second (m/sec)
Speed Deviation
meters per second (m/sec)PlaceboGabapentinDiphenhydramine CitrateTriazolam
Speed Deviation0.9 ± 0.30.9 ± 0.31.0 ± 0.31.3 ± 0.6
Statistical analysis
  • Placebo vs Triazolam · Wilcoxon Rank Sum test · p = <0.001 (Statistical comparison was performed at a two-sided significance level of 0.05.) · Hodges-lehman estimate: 0.36 · 95% CI 0.26 to 0.47Hodges-Lehman estimate of treatment difference was reported.
  • Placebo vs Gabapentin · Hodges-lehman estimate: -0.01 · 95% CI -0.07 to 0.05Hodges-Lehman estimate of treatment difference was reported.
  • Gabapentin vs Diphenhydramine Citrate · Wilcoxon Rank Sum test · p = 0.012 (Statistical comparison was performed at a two-sided significance level of 0.05.) · Hodges-lehman estimate: 0.07 · 95% CI 0.02 to 0.12Hodges-Lehman estimate of treatment difference was reported.
  • Placebo vs Diphenhydramine Citrate · Wilcoxon Rank Sum test · p = 0.014 (Statistical comparison was performed at a two-sided significance level of 0.05.) · Hodges-lehman estimate: 0.06 · 95% CI 0.01 to 0.12Hodges-Lehman estimate of treatment difference was reported.
SecondaryLane Exceedance

Driving performance assessment for the participants were measured by simulated driving test using Cognitive Research Corporation Driving Simulator (CRCDS-MiniSim). The assessment was performed after 45 minutes of awakening from approximately 6.5 hours of sleep on testing day (after 7.25 hours of study drug administration). Mean lanes excursed/exceeded was reported in the outcome measure.

Time frame:
7.25 hours post-dose
Reported as:
Mean · lanes exceeded
Lane Exceedance
lanes exceededPlaceboGabapentinDiphenhydramine CitrateTriazolam
Lane Exceedance37.8 ± 45.946.7 ± 58.552.4 ± 62.0147.7 ± 113.6
Statistical analysis
  • Placebo vs Triazolam · Wilcoxon Rank Sum test · p = <0.001 (Statistical comparison was performed at a two-sided significance level of 0.05.) · Hodges-lehman estimate: 103.25 · 95% CI 72.00 to 130.50Hodges-Lehman estimate of treatment difference was reported.
  • Placebo vs Gabapentin · Hodges-lehman estimate: 5.00 · 95% CI -4.00 to 16.50Hodges-Lehman estimate of treatment difference was reported.
  • Gabapentin vs Diphenhydramine Citrate · Wilcoxon Rank Sum test · p = 0.213 (Statistical comparison was performed at a two-sided significance level of 0.05.) · Hodges-lehman estimate: 3.00 · 95% CI -3.00 to 9.00Hodges-Lehman estimate of treatment difference was reported.
  • Placebo vs Diphenhydramine Citrate · Wilcoxon Rank Sum test · p = 0.003 (Statistical comparison was performed at a two-sided significance level of 0.05.) · Hodges-lehman estimate: 11.00 · 95% CI 4.00 to 20.50Hodges-Lehman estimate of treatment difference was reported.

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—0/58 (0%)3/58 (5.2%)
Gabapentin—0/55 (0%)2/55 (3.6%)
Diphenhydramine Citrate—0/57 (0%)3/57 (5.3%)
Triazolam—0/56 (0%)10/56 (17.9%)
Most frequent other events
Showing 10 of 12
Most frequent other events
EventPlaceboGabapentinDiphenhydramine CitrateTriazolam
SomnolenceNervous system disorders0/580/551/576/56
LethargyNervous system disorders0/580/550/573/56
NauseaGastrointestinal disorders0/582/551/572/56
Sensation of foreign bodyGeneral disorders0/580/550/571/56
DizzinessNervous system disorders0/580/550/571/56
HeadacheNervous system disorders0/580/551/571/56
Intervertebral disc protrusionMusculoskeletal and connective tissue disorders0/580/551/570/56
Vision blurredEye disorders1/580/550/570/56
Abdominal pain upperGastrointestinal disorders1/580/550/570/56
Dry mouthGastrointestinal disorders1/580/550/570/56

Baseline characteristics

Intent to Treat (ITT) population included all randomized participants who received at least 1 dose of investigational product and provided any data post-randomization.

Age, Continuous
Age, Continuous(years)Entire Study Population
Mean41.1 ± 9.0
Sex: Female, Male
Sex: Female, Male(Participants)Entire Study Population
Female13
Male46
08

Study locations

4 sites
  • Baptist Sleep Centers, LLP
    South Miami, Florida 33143, United States
  • Miami Research Associates
    South Miami, Florida 33143, United States
  • NeuroTrials Research Sleep Lab
    Atlanta, Georgia 30342, United States
  • NeuroTrials Research, Inc.
    Atlanta, Georgia 30342, United States
09

References and documents

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2013 to primary completion in Dec 2013, 4 months.

Results were first posted in Feb 2021, 7 years 1 month after primary completion. A results delay was requested in Dec 2014.

Of 29 industry-sponsored phase 3 interventional studies under Sleep Initiation and Maintenance Disorders, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 25. This study's 4 months is below that.

Counting every sponsor, half of 42 studies reached it within 19 months; a quarter within 15 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 25, 2013
First posted
Jun 27, 2013
StartActual
Jul 29, 2013
Primary completionActual
Dec 14, 2013
CompletionActual
Dec 14, 2013
Results delay requested
Dec 15, 2014
Results first posted
Feb 5, 2021
Last update
Feb 21, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 21, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01888497
Responsible party
Sponsor
First posted
Jun 27, 2013
Start date
Jul 29, 2013
Primary completion
Dec 14, 2013
Completion
Dec 14, 2013
Results posted
Feb 5, 2021
Last update
Feb 21, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Gabapentin · Diphenhydramine

Start the discussion